Illumina, Inc (NASDAQ:ILMN) Extends Profit Recovery While Clinical Demand Accelerates
![]() |
Illumina shows momentum through improving instrument placements and margin expansion, supported by cash generation and a fresh $1.5 billion repurchase authorization. Near-term technicals suggest continued upside tempered by an above-target price signal. |








